See more : Adbri Limited (ABC.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Enochian Biosciences, Inc. (ENOB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enochian Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Wüstenrot & Württembergische AG (WWUEY) Income Statement Analysis – Financial Results
- Ami Organics Limited (AMIORG.BO) Income Statement Analysis – Financial Results
- Onelife Capital Advisors Limited (ONELIFECAP.NS) Income Statement Analysis – Financial Results
- DCP Midstream, LP (DCP) Income Statement Analysis – Financial Results
- Coral India Finance and Housing Limited (CORALFINAC.BO) Income Statement Analysis – Financial Results
Enochian Biosciences, Inc. (ENOB)
About Enochian Biosciences, Inc.
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 42.77K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 121.86K | 113.50K | 123.59K | 391.42K | 366.27K | 71.71K | 18.48K | 14.53K | 32.67K | 314.64K | 0.00 | 0.00 |
| Gross Profit | -121.86K | -113.50K | -123.59K | -391.42K | -366.27K | -71.71K | -18.48K | -14.53K | 10.10K | -314.64K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 23.62% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.71M | 4.17M | 8.37M | 15.72M | 4.69M | 2.50M | 616.96K | 62.76K | 804.19K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 24.17M | 15.32M | 14.33M | 7.56M | 7.12M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 383.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 24.56M | 15.32M | 14.33M | 7.56M | 7.12M | 8.42M | 2.60M | 2.32M | 1.33M | 2.11M | 37.09K | 29.95K |
| Other Expenses | 54.37M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 81.64M | 19.60M | 22.83M | 23.40M | 11.92M | 10.92M | 3.22M | 2.39M | 2.13M | 2.11M | 37.09K | 29.95K |
| Cost & Expenses | 81.64M | 19.60M | 22.83M | 23.40M | 11.92M | 10.99M | 3.24M | 2.40M | 2.16M | 2.43M | 37.09K | 29.95K |
| Interest Income | 0.00 | 0.00 | 122.04K | 13.18K | 50.30K | 73.49K | 45.82K | 0.00 | 0.00 | 5.94K | 0.00 | 0.00 |
| Interest Expense | 1.01M | 706.96K | 372.84K | 379.61K | 104.28K | 43.00 | 143.26K | 26.26K | 2.36K | 84.55K | 497.00 | 0.00 |
| Depreciation & Amortization | 121.86K | 113.50K | 123.59K | 123.53K | 366.27K | 71.71K | 18.48K | 14.53K | 27.40K | 45.20K | 0.00 | 0.00 |
| EBITDA | -79.52M | -19.48M | -22.70M | -23.28M | -11.51M | -17.94M | -5.31M | -2.39M | -2.17M | -2.42M | -37.09K | -29.95K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,894.99% | 0.00% | 0.00% | 0.00% |
| Operating Income | -81.64M | -38.56M | -116.08M | -23.40M | -11.92M | -10.99M | -3.24M | -2.40M | -2.12M | -2.43M | -37.09K | -29.95K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,959.04% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 989.12K | -1.13M | 2.65M | -3.45M | 507.41K | -7.03M | -3.19M | 192.72K | -77.10K | -119.20K | -497.00 | 0.00 |
| Income Before Tax | -80.65M | -39.68M | -113.43M | -26.85M | -11.42M | -18.02M | -6.42M | -2.21M | -2.20M | -2.55M | -37.59K | -29.95K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,139.30% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 706.96K | 34.00 | -125.28K | 104.28K | 1.00 | -111.72K | -64.88K | -462.79K | -177.54K | 0.00 | 0.00 |
| Net Income | -80.65M | -39.68M | -113.43M | -26.72M | -11.42M | -18.02M | -6.31M | -2.14M | -1.74M | -2.37M | -37.59K | -29.95K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,057.24% | 0.00% | 0.00% | 0.00% |
| EPS | -0.84 | -0.71 | -2.16 | -0.57 | -0.25 | -0.48 | -0.29 | -0.17 | -0.18 | -0.32 | -0.01 | 0.00 |
| EPS Diluted | -0.84 | -0.71 | -2.16 | -0.57 | -0.25 | -0.48 | -0.29 | -0.17 | -0.18 | -0.32 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 96.25M | 56.27M | 52.53M | 47.17M | 46.33M | 37.55M | 21.94M | 12.27M | 9.53M | 7.50M | 5.00M | 10.44M |
| Weighted Avg Shares Out (Dil) | 96.25M | 56.27M | 52.53M | 47.17M | 46.33M | 37.55M | 21.94M | 12.27M | 9.53M | 7.50M | 5.00M | 10.44M |
3 Doomed Biotech Stocks Destined for Disaster
The world of biotech stocks is notoriously difficult to predict. History is littered with companies that appeared destined for superstar status only to crash and burn.
ENOB FINAL DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Enochian BioSciences, Inc. Investors to Secure Counsel Before Important September 26 Deadline in Securities Class Action – ENOB
NEW YORK, Sept. 14, 2022 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Enochian BioSciences, Inc. (NASDAQ: ENOB) between January 17, 2018 and June 27, 2022, both dates inclusive, (the...
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Enochian BioSciences, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – ENOB
NEW YORK–(BUSINESS WIRE)–WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Enochian BioSciences, Inc. (NASDAQ: ENOB) between January 17, 2018 and June 27, 2022, both dates inclusive, (the “Class Period”), including common stock...
'Murder-For-Hire Conspiracy': Why Enochian Biosciences Stock Is Plunging
Enochian Biosciences Inc (NASDAQ: ENOB) shares are trading lower Wednesday after Hindenburg Research issued a bearish report on the company. Last week, federal prosecutors announced the arrest of two men being charged in a "murder-for-hire" conspiracy, which resulted in the.
ENOB Stock Gains 20% Following Founder Arrest, Hindenburg Short
Enochian Bioscience is in the green today following the shocking arrest of the company founder earlier this week. ENOB stock closed up 20%.
6 Stocks Halted In Wednesday's Session: Here's Why
A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore and bring order to the markets.
ENOB Stock: Why The Price Increased Today
The stock price of Enochian Biosciences Inc (NASDAQ: ENOB) increased by over 3% pre-market today. This is why it happened.
Enochian BioSciences Announces the Successful Completion of an FDA Pre-IND for a Potential Cure for HIV: The Second Pre-IND in 1 month
Company encouraged by clear path to IND in near-term following its review of the FDA's Center for Biologics Evaluation and Research written comments Company encouraged by clear path to IND in near-term following its review of the FDA's Center for...
Scientific Advisory Board Member Resigns Due to Conflict with Responsibilities with Important Public Sector Entity
LOS ANGELES, Oct. 15, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, announced that Dr. Peter Piot has resigned as Chairperson of the Respiratory...
Fireside Chat with Enochian BioSciences' CEO, Dr. Mark Dybul at H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference
LOS ANGELES, Oct. 12, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company presentation to investors at...
Source: https://incomestatements.info
Category: Stock Reports